One Percent of Its Own Vaccines

Africa consumes approximately 25% of the world's vaccines but produces less than 1% domestically, making the continent structurally dependent on export decisions by manufacturers in Europe, India, and the United States. During COVID-19, that dependence translated directly into a 16% vaccination rate against 60–80% achieved in high-income countries, not because vaccines were unavailable globally but because export prioritization left Africa at the back of the queue. The African Union has set a target of 60% local vaccine production by 2040, but the gap between current capacity and that target is not primarily a technical problem — it is a market structure, financing, and regulatory harmonization problem that technical investments alone cannot close.

Drug product manufacturing capacity on the continent actually decreased by 40% between 2023 and 2024, the wrong direction relative to the AU target. The continent-wide vaccine manufacturing workforce is estimated at 2,000–3,000 employees — a number that would need to increase by an order of magnitude to support 60% local production. Only 5 of 25 identified African vaccine manufacturers have received meaningful commercial-scale technology transfers, and antigen production capacity — the most technically complex stage — remains very limited outside of a handful of facilities. The structure of Gavi's advance market commitments creates a price floor problem: African manufacturers cannot compete on cost without the production scale they cannot achieve without market access they cannot get without competitive pricing.

WHO established an mRNA technology transfer hub at Afrigen Biologics in South Africa in 2021, but the programme produced only microliters of experimental product through its early phases, and Moderna and Pfizer declined to share proprietary mRNA formulation know-how with the hub. BioNTainers — modular containerized mRNA manufacturing units — were deployed to Rwanda and Senegal as a decentralized production model, but the technology still depends on lipid nanoparticle supply chains concentrated outside Africa. Technology transfer agreements have generally involved fill-and-finish operations (the final packaging step) rather than antigen production, meaning African facilities are being integrated into the least technically complex and lowest-value stage of the manufacturing chain. Regulatory fragmentation across 55 national medicines authorities means a product approved in one African country cannot be marketed continent-wide without repeated regulatory submissions, destroying the economics of regional manufacturing at scale. The African Medicines Agency was established by treaty in 2019 but had not reached full operational status as of early 2026.

Regulatory harmonization through a functional African Medicines Agency with mutual recognition agreements would fundamentally change the economics of manufacturing for African markets by creating a continental addressable market. Upstream technology transfer — antigen production and formulation, not just fill-and-finish — is required to build genuine manufacturing capability rather than assembly dependency. Public procurement coordination through the African Vaccine Acquisition Trust model, if given binding advance purchase commitment authority, could provide the demand-side guarantee that makes manufacturing investment viable.

A market design team could model the Gavi pricing problem: at what production volumes and with what procurement guarantees do African manufacturers become cost-competitive, and what policy instruments could create those conditions? A regulatory mapping team could document the current state of medicines regulatory harmonization across AU member states and identify the minimum mutual recognition architecture needed to create a functional continental market. A technology transfer analysis team could compare what was actually transferred in the five commercial-scale deals versus what antigen production capability requires, and identify the specific knowledge and equipment gaps.